12:00 AM
 | 
Jan 09, 2006
 |  BioCentury  |  Tools & Techniques

Proteins made your way

Pharma companies are clearly interested in developing next generation protein and antibody therapeutics, and they are piggybacking on the work being done at a number of startups to do so. Indeed, rather than entering into single molecule deals, many of these partnerships are more broadly focused.

The latest example is last week's deal between Wyeth and Trubion Pharmaceuticals Inc. to discover small modular immunopharmaceuticals (SMIPs) to treat inflammatory diseases and cancer. In addition to potentially churning out multiple drug candidates, the companies will...

Read the full 408 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >